Rep. Tim Moore Buys Genprex (NASDAQ:GNPX) Stock

Representative Tim Moore (R-North Carolina) recently bought shares of Genprex (NASDAQ:GNPX). In a filing disclosed on November 12th, the Representative disclosed that they had bought between $15,001 and $50,000 in Genprex stock on October 29th. The trade occurred in the Representative’s “SCHWAB ONE” account.

Representative Tim Moore also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Verizon Communications (NYSE:VZ) on 10/31/2025.
• Purchased $15,001 – $50,000 in shares of LGI Homes (NASDAQ:LGIH) on 10/30/2025.
• Sold $100,001 – $250,000 in shares of Hyster-Yale (NYSE:HY) on 10/24/2025.
• Sold $50,001 – $100,000 in shares of Krispy Kreme (NASDAQ:DNUT) on 10/22/2025.
• Purchased $15,001 – $50,000 in shares of Hyster-Yale (NYSE:HY) on 10/14/2025.
• Purchased $15,001 – $50,000 in shares of Verizon Communications (NYSE:VZ) on 10/10/2025.
• Purchased $15,001 – $50,000 in shares of Hyster-Yale (NYSE:HY) on 10/10/2025.
• Purchased $50,001 – $100,000 in shares of Hyster-Yale (NYSE:HY) on 10/8/2025.
• Purchased $50,001 – $100,000 in shares of Verizon Communications (NYSE:VZ) on 10/7/2025.
• Sold $50,001 – $100,000 in shares of Hyster-Yale (NYSE:HY) on 9/19/2025.

Genprex Price Performance

Shares of NASDAQ:GNPX traded down $0.29 during trading on Wednesday, reaching $3.40. The company had a trading volume of 236,352 shares, compared to its average volume of 265,127. Genprex has a fifty-two week low of $3.32 and a fifty-two week high of $68.50. The stock’s fifty day moving average price is $10.06 and its 200 day moving average price is $11.68. The firm has a market capitalization of $4.25 million, a price-to-earnings ratio of -0.13 and a beta of -0.74.

Genprex (NASDAQ:GNPX) last issued its earnings results on Friday, November 14th. The company reported ($5.00) earnings per share for the quarter, beating the consensus estimate of ($12.50) by $7.50. On average, equities analysts anticipate that Genprex will post -5.7 EPS for the current fiscal year.

Institutional Investors Weigh In On Genprex

An institutional investor recently raised its position in Genprex stock. Susquehanna International Group LLP increased its stake in shares of Genprex (NASDAQ:GNPX) by 11.7% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 340,056 shares of the company’s stock after purchasing an additional 35,661 shares during the quarter. Susquehanna International Group LLP owned approximately 27.20% of Genprex worth $58,000 as of its most recent filing with the Securities and Exchange Commission. 14.05% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on GNPX shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Genprex in a research note on Wednesday, October 8th. Wall Street Zen upgraded shares of Genprex to a “sell” rating in a research report on Saturday, October 18th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has an average rating of “Sell”.

About Representative Moore

Timothy K. Moore (Republican Party) is a member of the U.S. House, representing North Carolina’s 14th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Moore (Republican Party) ran for election to the U.S. House to represent North Carolina’s 14th Congressional District. He won in the general election on November 5, 2024.

Moore served as speaker of the House from 2015 to 2025.

Timothy Moore earned his B.A. from the University of North Carolina-Chapel Hill in 1992 and his J.D. from the Oklahoma City University School of Law in 1995. His professional experience includes working as an attorney.

Genprex Company Profile

Genprex, Inc, a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes.